Minaris Achieves 100% Manufacturing Success Rate for Chimeric Therapeutics' CDH17 CAR-T Cancer Program
核心洞察
Minaris (搜索) has achieved a 100% batch manufacturing and release success rate over five years of collaboration supporting Chimeric Therapeutics (搜索)' CDH17 (搜索)-targeted autologous CAR-T program for gastrointestinal cancers.
The partnership has maintained a consistent clinical manufacturing cadence of approximately one autologous batch per month, with plans to expand to two batches monthly based on patient enrollment.
CHM CDH17 (搜索) is a first-in-class, third-generation CAR-T therapy currently being studied in a Phase 1A/1B clinical trial for gastrointestinal and neuroendocrine tumors, with preclinical data showing complete tumor eradication in seven cancer types in mice.
Minaris (搜索), a global cell and gene therapy contract development and manufacturing organization, has achieved a remarkable 100% batch manufacturing and release success rate in its five-year collaboration with Chimeric Therapeutics (搜索) supporting the Australian company's CDH17 (搜索)-targeted autologous CAR-T program for gastrointestinal cancers.
The partnership has sustained a consistent clinical manufacturing cadence of approximately one autologous batch per month throughout the collaboration period, with planned expansion to two batches per month based on patient enrollment and trial requirements for the ongoing Phase 1A/1B study targeting gastrointestinal cancers, including colorectal and gastric cancer (搜索) as well as neuroendocrine cancers.
Manufacturing Excellence in Autologous Cell Therapy
Minaris (搜索) provides comprehensive end-to-end GMP manufacturing and full release testing for the Phase 1A/1B clinical study at its Philadelphia site. The partnership has encompassed process and analytical development, as well as technology transfer, enabling a seamless transition to GMP operations.
"This performance reflects what matters most in autologous cell therapy manufacturing: tight coordination, consistent execution, and a partner able to adapt workflows while maintaining rigorous GMP discipline," said Orla Cloak, CEO of Minaris (搜索). "We remain focused on supporting Chimeric as the CDH17 (搜索) program advances through clinical development, with an emphasis on reliable supply and dependable product release."
The collaboration brings together cross-functional expertise across process development, analytical development, manufacturing, quality assurance, quality control, supply chain, and program management. Chimeric utilized Minaris (搜索)' established autologous CAR-T production workflow as a foundation and collaborated closely with technical teams to tailor the process to its drug product.
First-in-Class CDH17 CAR-T Development
CHM CDH17 (搜索) represents a first-in-class, third-generation CDH17 (搜索) CAR-T therapy invented at the University of Pennsylvania in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute. Preclinical evidence published by Dr. Hua and colleagues in March 2022 in Nature Cancer demonstrated complete eradication of tumors in seven types of cancer in mice.
The therapy is currently being studied in a Phase 1/2 clinical trial for gastrointestinal and neuroendocrine tumors that was initiated in 2024. Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (搜索), emphasized the partnership's impact: "Minaris (搜索) has been a trusted partner across key phases of our program, including the transition from process and analytical development into GMP. Their operational reliability and collaborative approach has helped us maintain a tight production and release schedule, supporting consistent delivery of product for patient infusion."
Broader Cell Therapy Portfolio
Chimeric Therapeutics (搜索) maintains a diversified portfolio that includes first-in-class autologous CAR-T cell therapies and best-in-class allogeneic NK cell therapies, with four clinical stage programs across multiple oncology disease areas. The company's CHM CORE-NK (搜索) platform represents a potentially best-in-class, clinically validated NK cell platform, with Phase 1A clinical trial data published in March 2022 demonstrating safety and efficacy in blood cancers (搜索) and solid tumors (搜索).
Based on promising activity signals from the initial trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next-generation NK and CAR-NK assets.
The operational results underscore the critical importance of manufacturing partnerships in autologous cell therapy development, where consistent production and release schedules directly impact patient treatment timelines and clinical trial progression.